| Publications | PubMed=7622289; DOI=10.1002/ijc.2910620208
De Waard-Siebinga I., Blom D.-J.R., Griffioen M., Schrier P.I., Hoogendoorn E., Beverstock G.C., Danen E.H.J., Jager M.J.
Establishment and characterization of an uveal-melanoma cell line.
Int. J. Cancer 62:155-161(1995) PubMed=15714118; DOI=10.1097/00008390-200502000-00006
Lopez-Velasco R., Morilla-Grasa A., Saornil-Alvarez M.A., Ordonez J.L., Blanco G., Rabano G., Fernandez N., Almaraz A.
Efficacy of five human melanocytic cell lines in experimental rabbit choroidal melanoma.
Melanoma Res. 15:29-37(2005) PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016
White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.
Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.
Cancer Genet. Cytogenet. 168:11-21(2006) PubMed=17487557; DOI=10.1007/s10585-007-9072-z
Marshall J.-C., Nantel A., Blanco P., Ash J., Cruess S.R., Burnier M.N. Jr.
Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis.
Clin. Exp. Metastasis 24:353-362(2007) PubMed=19340423; DOI=10.1007/s00262-009-0701-z
Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T., Ruiz-Cabello F., Garrido F., Garcia-Lora A.
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
Cancer Immunol. Immunother. 58:1507-1515(2009) PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x
Griewank K.G., Yu X., Khalili J., Sozen M.M., Stempke-Hale K., Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.
Genetic and molecular characterization of uveal melanoma cell lines.
Pigment Cell Melanoma Res. 25:182-187(2012) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012) PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011
Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I., Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R., Salvi S., Truini M., Poggi A., Pfeffer U.
Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
Eur. J. Cancer 49:3353-3365(2013) PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013) PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004
Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A., Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N., Piperno-Neumann S., Mariani P., Sastre X., Decaudin D., Roman-Roman S.
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
Mol. Oncol. 8:1508-1520(2014) PubMed=28018010
Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.
Uveal melanoma cell lines: where do they come from? (an American Ophthalmological Society thesis).
Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016) PubMed=32430489; DOI=10.1158/1535-7163.MCT-19-1016
Teh J.L.F., Purwin T.J., Han A., Chua V., Patel P., Baqai U., Liao C., Bechtel N., Sato T., Davies M.A., Aguirre-Ghiso J.A., Aplin A.E.
Metabolic adaptations to MEK and CDK4/6 cotargeting in uveal melanoma.
Mol. Cancer Ther. 19:1719-1726(2020) PubMed=36164296; DOI=10.1016/j.dib.2022.108592
Fei X.-F., Xie X.-T., Ji X.-Y., Tian H.-Y., Sun F., Jiang D.-Y., Wang Z.-M., Huang Q.
Quantitative proteomic dataset of whole protein in three melanoma samples of 92.1, 92.1-A and 92.1-B.
Data Brief 45:108592.1-108592.7(2022) |
|---|
